Search results
Results from the WOW.Com Content Network
Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth [8] and also is considered to cause pulmonary hypertension. [9] In phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients.
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...
Last month, the FDA approved Biogen’s Alezheimer’s disease drug Aducanumab, in a controversial decision that went against the advisory committee’s recommendation. When looking at the case of ...
The stock of FibroGen (NAS:FGEN, 30-year Financials) is estimated to be possible value trap, according to GuruFocus Value calculation.
Fibrinogen beta chain, also known as FGB, is a gene found in humans and most other vertebrates with a similar system of blood coagulation.. The protein encoded by this gene is the beta component of fibrinogen, a blood-borne glycoprotein composed of three pairs of nonidentical polypeptide chains.
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...
We feel now is a pretty good time to analyse FibroGen, Inc.'s (NASDAQ:FGEN) business as it appears the company may be... Market Sentiment Around Loss-Making FibroGen, Inc. (NASDAQ:FGEN) Skip to ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.